Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ApaTech hires three senior executives

This article was originally published in Clinica

Executive Summary

Orthobiologics company ApaTech (Hertfordshire, UK) has appointed Jill Schiaparelli vice-president of commercial strategy and business development (global) and Melanie Marshall is named vice-president for clinical operations — both will join the company’s senior management team. And Todd Clearwater joins the US office as vice-president for national sales. Ms Schiaparelli joins from Johnson & Johnson, where she held a number of global strategy and marketing positions; Ms Marshall joins from Boston Scientific, where she was responsible for clinical strategy and execution across several divisions; and Mr Clearwater was most recently senior vice-president of sales at Interventional Spine. ApaTech specialises in developing and manufacturing synthetic bone repair material.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT041130

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel